BioCentury
ARTICLE | Company News

Evotec, Harvard deal

May 20, 2013 7:00 AM UTC

Evotec partnered with the university to discover and develop small molecule inhibitors of peptidoglycan biosynthesis. Harvard will contribute undisclosed research and IP relating on proprietary assays, small molecule hits and x-ray crystallographic tools, while Evotec will contribute its drug discovery infrastructure and experience in the antibacterial space. Evotec will have rights to the antibacterials resulting from the deal. The partners declined to disclose details. ...